Quick Search (by title or disease)
  

Go to Advanced Search for more options.

Clinical Trials Help

Contact our Cancer Information Line nurse with your questions about open or upcoming clinical trials, second opinions, or patient referrals.
ccinfo@umn.edu • 612-624-2620 • 1-888-226-2376

  Sip Protocol

Masonic Cancer Research Center
ccinfo@umn.edu • 612-624-2620 • 1-888-226-2376

Back to Search Instructions

Protocol No. 2015CG039 Principal Investigator McClune, Brian
Phase Phase II
Age Group Adult Scope National
Secondary Protocol No. CTN 1302
Title MT2015-11 : Multicenter Phase II, Double-blind Placebo Controlled Trial of Maintenance Ixazomib after Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Multiple Myeloma (CTN1302)
Objective To compare progression-free survival as a time to event endpoint from the time of randomization between patients randomized to ixazomib versus placebo maintenance in patients with high risk multiple myeloma.
Applicable Disease Sites Multiple Myeloma
Therapies Involved Blood and Marrow Transplant
Drugs Involved Bortezomib (Velcade)
FLUDARABINE (FLUDARA)
MELPHALAN (ALKERAN)
Status Open
Participating Institutions Masonic Cancer Center
Treatment Type Treatment
Contact Timothy Krepski Phone:612-273-2800
Email:tkrepsk1@fairview.org